Carcino Embryonic Antigen (CEA)
CEA is a protein that can be elevated in certain cancers, especially colorectal cancer. This blood test is primarily used to monitor cancer treatment and detect recurrence rather than for initial screening.
- Free home collection
- Physician-reviewed report
24 Hours
Turnaround
Blood
Sample
What the Carcino Embryonic Antigen (CEA) test tells you
Carcinoembryonic antigen, usually shortened to CEA, is a sugar-coated protein that helps cells stick to one another. It is made in quantity by the developing gut before birth, and only in traces by healthy adult tissue. Some tumours switch the gene back on, so the protein reappears in the bloodstream where it can be measured. That is the whole basis of the test: it does not look for cancer cells directly, but for a substance that certain cancers release.
CEA is most closely associated with cancers of the colon and rectum, and it is here that it earns its place in routine care. It is measured before surgery to establish a starting point, then repeated at intervals afterwards. A value that falls after treatment and stays down is reassuring; one that climbs steadily across successive samples prompts imaging to look for disease that has returned. Because the direction of travel over several samples carries far more information than any single reading, results are always read in sequence rather than in isolation.
The protein is not exclusive to cancer. Smoking raises it, as do inflammatory bowel disease, chronic liver disease, pancreatitis and several benign lung conditions. Equally, a substantial share of colorectal tumours never produce much CEA at all, so an unremarkable result does not rule cancer out. For these reasons CEA is not used to screen people who have no symptoms and no diagnosis; it belongs to the follow-up of a known condition, alongside scans, endoscopy and your doctor's assessment.
Most commonly used to monitor treatment response in colorectal cancer patients and for early detection of recurrence after surgery.
- Tracking treatment response
Repeated during and after treatment for colorectal cancer, CEA indicates whether tumour burden is falling. A steady decline supports that the treatment is working.
- Watching for recurrence
After surgery intended to cure, serial measurements can flag returning disease before any symptom appears, prompting earlier imaging.
- Setting a baseline
A value taken before treatment shows whether this particular tumour secretes CEA at all, which decides how useful later readings will be.
- Clarifying uncertain scans
When imaging findings are ambiguous, the trend in CEA across successive samples adds context to the decision about what to do next.
Reasons your doctor may request the Carcino Embryonic Antigen (CEA) test
Your doctor may order this test for any of the reasons below. Some are routine checks, others follow specific symptoms or an earlier result.
Colorectal cancer follow-up
- You are being treated for colorectal cancer and your oncologist wants to follow the response.
- You have completed surgery for bowel cancer and are in a structured follow-up programme.
Suspected recurrence
- Imaging has raised a question about recurrence and your doctor wants supporting information.
Choosing a marker to follow
- You are being assessed for a cancer of the pancreas, stomach, lung or breast where CEA is one of several markers considered.
- Your specialist is deciding which tumour marker is worth following in your particular case.
A result in the Normal band, 0 to 3 ng/mL, is what most healthy non-smokers show and carries no meaning of its own; a substantial share of colorectal tumours never release much CEA, so it is not reassurance by itself. A result in the Borderline band, 3.1 to 5 ng/mL, is mildly raised and can occur simply because you smoke. A result in the High band, 5.1 to 1000 ng/mL, needs context: inflammatory bowel disease, chronic liver disease, pancreatitis, peptic ulcer disease and benign lung conditions all lift it with no cancer present. Because CEA is used to follow a cancer already diagnosed, the direction of travel across successive samples matters far more than a single reading, and follow-up samples should ideally be run by the same laboratory. Your doctor interprets it with imaging, examination, your smoking history and how you feel.
Ranges are a guide: your physician interprets your result alongside your symptoms and history.
What a higher result can point to
- Colorectal cancer, particularly when disease is widespread rather than confined.
- Cancers of the pancreas, stomach, lung, breast, thyroid or ovary.
- Regular cigarette smoking, which lifts CEA in people with no cancer at all.
- Inflammatory bowel disease such as ulcerative colitis or Crohn's disease.
- Chronic liver disease, pancreatitis or peptic ulcer disease.
- Benign lung conditions including chronic bronchitis and emphysema.
These are possibilities, not diagnoses. A single value outside the reference range is interpreted alongside your symptoms, history and other tests: your doctor decides what it means for you.
What this test cannot tell you
- A low or undetectable CEA does not exclude cancer, because many tumours never release it.
- Non-cancerous conditions and smoking raise CEA, so a single high value is not evidence of malignancy.
- Results from different assay platforms are not interchangeable, so follow-up samples should ideally be run by the same laboratory.
- It is not a screening test and should not be ordered to look for cancer in someone who is well.
Risks of the blood draw
- Mild bruising or brief soreness where the needle went in.
- Occasional lightheadedness, which settles after a few minutes of rest.
- Bleeding or infection at the site, which is rare with sterile single-use equipment.
- 1CEA is a monitoring tool for a cancer already diagnosed, not a way of finding one.
- 2The trend across repeated samples matters far more than any single result.
- 3Smoking, bowel inflammation and liver disease can all lift the value without cancer being present.
- 4An undetectable result is expected in most healthy adults and carries no meaning on its own.
- 5Your oncologist interprets CEA together with imaging, examination and how you feel.
- Tumour MarkersCA-19-9
CA-19-9 is a tumour marker commonly associated with pancreatic cancer. It can also be elevated in other gastrointestinal cancers and some…
230View - Tumour MarkersCA-15-3
CA-15-3 is a tumour marker primarily used to monitor breast cancer treatment and detect recurrence. Rising levels may indicate disease progression. A…
230View - Tumour MarkersAlpha Fetoprotein (AFP)
Alpha-Fetoprotein (AFP) is a protein produced mainly by the fetal liver. Elevated levels in adults may indicate certain liver conditions or be used…
140View - Stool StudiesOccult Blood (Fecal Occult Blood/FOB)
This stool test detects hidden (occult) blood that is not visible to the naked eye. It is a key screening tool for colorectal cancer and can also…
80View
Frequently Asked Questions
Everything you need to know about the Carcino Embryonic Antigen (CEA) test. Can't find what you're looking for?
Talk to our team→No. It is neither sensitive nor specific enough for that job: many early bowel cancers make little CEA, and several harmless conditions raise it. Bowel cancer screening is done with stool testing and colonoscopy; CEA has its role after a diagnosis has been made.
Not on its own. Small fluctuations arise from assay variation, smoking and intercurrent illness. Doctors look for a rise that is sustained across repeat samples before acting, and confirm any concern with imaging.
Yes. Regular smokers tend to run higher CEA than non-smokers with no cancer present, and the value often drifts down after quitting. This is one reason your doctor asks about tobacco use when reading the report.
Some tumours simply do not produce this protein. If your pre-treatment value was not raised, CEA will not be a useful marker to follow in your case, and your team will monitor you with imaging and other tests instead.
CEA is a protein that can be elevated in certain cancers, especially colorectal cancer. This blood test is primarily used to monitor cancer treatment and detect recurrence rather than for initial screening.
Most commonly used to monitor treatment response in colorectal cancer patients and for early detection of recurrence after surgery.
No, fasting is not required for the Colorectal Cancer Marker test, so you can eat and drink normally beforehand.
The Colorectal Cancer Marker test uses a blood sample, collected quickly by our DHA-licensed phlebotomist with minimal discomfort.
Results for the Colorectal Cancer Marker test are typically ready within 24 hours. You will receive a secure digital report, and your Smart Report highlights anything outside the normal range.
The Colorectal Cancer Marker test is AED 150, which includes free home sample collection and a physician-reviewed report. You can also build a custom panel and pay only for the markers you choose.
Yes. A DHA-licensed phlebotomist can collect your sample at home or the office anywhere in Dubai at no extra cost, 7 days a week. See how it works.
It is commonly chosen by adults & at-risk groups. If you are not sure it is right for you, our care team is happy to advise.
Add the Colorectal Cancer Marker test to your cart and complete the short booking wizard, choosing home collection or a lab visit. Guest checkout lets you book without creating an account.
Yes. It is processed at our EIAC-accredited laboratory (ISO 15189:2022) under DHA license 0046381 and verified by board-certified pathologists.
Every report includes reference ranges and plain-language notes. If you have questions, our care team can arrange a clinician review: just get in touch.
Absolutely. Add it to a curated health package or bundle it with any of our 160+ biomarkers, often from a single sample in one visit.